Ⓐ
PeptiBrief
Endogenous peptide

Apelin-13

A potent endogenous apelin-receptor agonist studied for acute cardiovascular and renal effects.

Sequence
Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe
Formula
C69H111N23O16S
Molecular weight
1550.8 Da

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Possible adverse effects include hypotension, dizziness and altered cardiac or renal haemodynamics. Long-term exogenous safety is unknown.

Regulation
  • Not approved as a general cardiovascular, renal, metabolic or neuroprotective medicine.

References

  1. Cardiovascular and renal effects of apelin in chronic kidney disease · 2024
  2. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand · 2019
Last reviewed
12 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.